ORIC Pharmaceuticals reports Q3 2021 cash of $296.5M, ORIC-101 early clinical data, and upcoming pipeline milestones

Oric Pharmaceuticals, Inc.

2022-Q3 EPS reported -$1.49

Cash, cash equivalents and investments of $296.5 million, expected to fund operations into 2024.
Initial Phase 1b data for ORIC-101 combo with enzalutamide showed safe profile and antitumor activity in 6 of 8 key patients.
R&D expenses $12.9M (Q3 2021) vs $8.8M (Q3 2020); G&A expenses $5.6M vs $3.8M.
Anticipated Q4 2021 milestones: initiate Phase 1 trial for ORIC-533 in multiple myeloma and file IND for ORIC-944.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.